The common stock of DKK 650 million, or 65 million shares, was unchanged from the level at the end of 2007.
|Novozymes’ stock (DKK)||2008||2007|
|Total market value, year-end (billion)*||22.7||31.6|
|Earnings per share, diluted||16.86||16.47|
|Dividend per share||5.25**||5.00|
|* Excluding A stock|
The average daily trading volume of Novozymes’ stock was 283,218 shares, or DKK 124 million, making it the sixth most actively traded stock on NASDAQ OMX Copenhagen A/S. At year-end 2008, the total market value of Novozymes was DKK 22.7 billion.
Novozymes’ stock price fell 28% during the year. In comparison, the return on the OMXC20 was -46%, Dow Jones Chemicals Europe Index -38%, and NASDAQ Biotechnology Index -14%.
Over the last five years, Novozymes’ stock has generated an average annual return to shareholders, including dividends, of more than 21%. This can be compared to the five-year average return of 0% for the OMXC20, -3% for MSCI PAN Europe, -3% for Dow Jones World Sustainability Index, +8% for Dow Jones Chemicals Europe Index, and 0% for NASDAQ Biotechnology Index.